secwatch.observer — SEC 8-K summary
======================================

Issuer:     LUDWIG ENTERPRISES, INC. (LUDG)
CIK:        0001960262
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0001213900-25-057684
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ludwig Enterprises appoints Garth Lees-Rolfe as independent director
--------------------------------------------------------------------

- Garth Lees-Rolfe appointed independent director effective June 23, 2025.
- Over 19 years of finance/accounting experience; currently CFO of ABLi Therapeutics.
- Previously CFO of Inhibikase Therapeutics (NASDAQ: IKT) and VP Finance at F-Star (NASDAQ: FSTX).
- Spent 16 years at Ernst & Young, most recently as Senior Manager; holds CPA and Chartered Accountant licenses.
- No family relationships with existing directors or executive officers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1960262/000121390025057684/0001213900-25-057684-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1960262/000121390025057684/ea0246925-8k_ludwig.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-057684

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer